{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:03:54Z","timestamp":1789621434934,"version":"build-2803163510"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction and objectives:<\/jats:title>\n                    <jats:p>Benign prostatic hyperplasia (BPH) and chronic prostatitis (CP) are common causes of lower urinary tract symptoms (LUTS) in men. This multicenter study evaluated the efficacy of an entomological extract-based treatment (EEBT) as monotherapy and in combination with standard drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>A total of 6375 men with LUTS (IPSS\u2009\u2a7e\u200910, Qmax 5\u201315\u2009mL\/s) were included; 1498 had BPH, 3060 had CP, and 1817 had both. Group I received EEBT monotherapy, while Group II underwent combination therapy with \u03b11-adrenergic blockers, NSAIDs, antibiotics, and other agents. Outcomes were assessed after 30\u2009days using NIH-CPSI, IPSS, IIEF-5, QoL, Qmax, prostate volume, and residual urine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Both regimens significantly improved LUTS. In BPH patients, monotherapy reduced prostate and residual urine volumes and improved IIEF-5, whereas combination therapy provided greater symptom relief. In CP patients, both regimens improved NIH-CPSI, IPSS, and urinary flow, with monotherapy showing superior QoL benefits. In men with BPH\u2009+\u2009CP, monotherapy favored erectile function, while combination therapy improved IPSS. All subgroups demonstrated significant gains in Qmax. Treatment was well tolerated; only mild Clavien\u2013Dindo grade I and II adverse events were reported, with no serious complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>EEBT is effective as both monotherapy and in combination therapy for LUTS associated with BPH and CP, supporting its role in personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603261421805","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:57:57Z","timestamp":1771045077000},"page":"421-425","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multicenter study on the effectiveness of entomological extract-based therapy in men with lower urinary symptoms associated with benign prostatic hyperplasia and chronic prostatitis"],"prefix":"10.1177","volume":"93","author":[{"given":"George","family":"Kasyan","sequence":"first","affiliation":[{"name":"Moscow Urology Center, Botkin Hospital, Moscow, Russia"},{"name":"Urology Department, Russian University of Medicine, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyubov","family":"Khodyreva","sequence":"additional","affiliation":[{"name":"Moscow Urology Center, Botkin Hospital, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-0653","authenticated-orcid":false,"given":"Bagrat","family":"Grigoryan","sequence":"additional","affiliation":[{"name":"Moscow Urology Center, Botkin Hospital, Moscow, Russia"},{"name":"Urology Department, Russian University of Medicine, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Dyakov","sequence":"additional","affiliation":[{"name":"Moscow Urology Center, Botkin Hospital, Moscow, Russia"},{"name":"Urology Department, Russian University of Medicine, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2016.04.001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.12.038"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13101"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10807.x"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002183"},{"key":"e_1_3_2_7_2","first-page":"84","article-title":"Combined treatment of lower urinary tract symptoms in men","volume":"5","author":"Kasyan GR","year":"2016","unstructured":"Kasyan GR, Khodyreva LA, Dudareva AA, et al. Combined treatment of lower urinary tract symptoms in men. Med Counc 2016; 5: 84\u201390.","journal-title":"Med Counc"},{"issue":"2","key":"e_1_3_2_8_2","first-page":"37","article-title":"Modern possibilities of combined therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia in men","volume":"3","author":"Kasyan GR","year":"2016","unstructured":"Kasyan GR, Konovalov IV. Modern possibilities of combined therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia in men. Res Pract Med 2016; 3(2): 37\u201344.","journal-title":"Res Pract Med"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2018.06.002"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.25881\/BPNMSC.2020.54.45.019"},{"issue":"8","key":"e_1_3_2_11_2","first-page":"493","article-title":"Clinical and economic impact of early versus delayed 5-Alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia","volume":"36","author":"Kruep EJ","year":"2011","unstructured":"Kruep EJ, Hogue SL, Eaddy MT, et al. Clinical and economic impact of early versus delayed 5-Alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. P T 2011; 36(8): 493\u2013507.","journal-title":"P T"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.18565\/urology.2021.1.39-44"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.35401\/2500-0268-2020-19-3-45-51"},{"issue":"3","key":"e_1_3_2_14_2","first-page":"34","article-title":"Effectiveness of adenoprosin in patients with benign prostatic hyperplasia, chronic prostatitis, and lower urinary tract symptoms","volume":"17","author":"Demidko YL","year":"2021","unstructured":"Demidko YL, Allenov SN, Uzhegov TA, et al. Effectiveness of adenoprosin in patients with benign prostatic hyperplasia, chronic prostatitis, and lower urinary tract symptoms. Eff Pharmacother 2021; 17(3): 34\u201341.","journal-title":"Eff Pharmacother"},{"issue":"4","key":"e_1_3_2_15_2","first-page":"337","article-title":"Efficacy evaluation of entomological drug adenoprosin\u00ae usage in combined treatment of patients with lower urinary tract symptoms due to benign prostate enlargement","volume":"11","author":"Al-Shukri AS","year":"2021","unstructured":"Al-Shukri AS, Kostyukov SV, Maksimova AV. Efficacy evaluation of entomological drug adenoprosin\u00ae usage in combined treatment of patients with lower urinary tract symptoms due to benign prostate enlargement. Urol Rep 2021; 11(4): 337\u2013344.","journal-title":"Urol Rep"},{"issue":"1","key":"e_1_3_2_16_2","first-page":"108","article-title":"Evaluation of the efficacy and safety of adenoprosin\u00ae in patients with category IIIA chronic prostatitis","volume":"16","author":"Kyzlasov PS","year":"2023","unstructured":"Kyzlasov PS, Abuev GG, Mustafaev AT. Evaluation of the efficacy and safety of adenoprosin\u00ae in patients with category IIIA chronic prostatitis. Exp Clin Urol 2023; 16(1): 108\u2013114.","journal-title":"Exp Clin Urol"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261421805","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603261421805","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603261421805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:33:23Z","timestamp":1789619603000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603261421805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/03915603261421805"],"URL":"https:\/\/doi.org\/10.1177\/03915603261421805","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]}}}